U.S. Markets close in 4 hrs 50 mins
  • S&P 500

    -8.44 (-0.22%)
  • Dow 30

    -106.84 (-0.35%)
  • Nasdaq

    -18.08 (-0.16%)
  • Russell 2000

    -10.41 (-0.61%)
  • Crude Oil

    +1.73 (+1.64%)
  • Gold

    -5.10 (-0.28%)
  • Silver

    -0.69 (-3.40%)

    -0.0092 (-0.8729%)
  • 10-Yr Bond

    -0.1060 (-3.57%)
  • Vix

    -0.07 (-0.24%)

    -0.0165 (-1.3583%)

    -0.4990 (-0.3676%)

    +245.53 (+1.28%)
  • CMC Crypto 200

    -3.95 (-0.94%)
  • FTSE 100

    -29.18 (-0.41%)
  • Nikkei 225

    -457.42 (-1.73%)

Those Who Purchased Psychemedics (NASDAQ:PMD) Shares A Year Ago Have A 26% Loss To Show For It

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Investors can approximate the average market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Psychemedics Corporation (NASDAQ:PMD) shareholders over the last year, as the share price declined 26%. That falls noticeably short of the market return of around 3.9%. Longer term investors have fared much better, since the share price is up 4.1% in three years. Even worse, it’s down 22% in about a month, which isn’t fun at all. This could be related to the recent financial results – you can catch up on the most recent data by reading our company report.

View our latest analysis for Psychemedics

To quote Buffett, ‘Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace…’ One way to examine how market sentiment has changed over time is to look at the interaction between a company’s share price and its earnings per share (EPS).

Unfortunately Psychemedics reported an EPS drop of 25% for the last year. This change in EPS is remarkably close to the 26% decrease in the share price. Therefore one could posit that the market has not become more concerned about the company, despite the lower EPS. Rather, the share price has approximately tracked EPS growth.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

NasdaqCM:PMD Past and Future Earnings, March 18th 2019
NasdaqCM:PMD Past and Future Earnings, March 18th 2019

It might be well worthwhile taking a look at our free report on Psychemedics’s earnings, revenue and cash flow.

What About Dividends?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings. It’s fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Psychemedics, it has a TSR of -23% for the last year. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

A Different Perspective

Investors in Psychemedics had a tough year, with a total loss of 23% (including dividends), against a market gain of about 3.9%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year’s performance may indicate unresolved challenges, given that it was worse than the annualised loss of 0.1% over the last half decade. We realise that Buffett has said investors should ‘buy when there is blood on the streets’, but we caution that investors should first be sure they are buying a high quality businesses. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.